![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Consider the four “P’s” of generic drugs that support the case for wider adoption of generics in the health system and beyond.
How Low Unit of Measure Can Streamline Your Patient Care
The benefits of buying in smaller units of measure and how to implement LUM.
By
Date
February 28, 2022
By: McKesson MedSurg Editorial Team
Read time: 6 minutes
For facilities with limited storage space issues, choosing a low unit of measure (LUM) approach is a best practice. when considering a LUM approach, it's important to understand the implications so there are no surprises, and the facility can plan for its needs accordingly. This helps mitigate the risk of getting caught shorthanded and ensure that pharmaceutical items meet drug supply chain security act (DSCSA) regulatory requirements.
In this article, gain a better understanding of LUM, its benefits, as well as the risks to help you make an informed decision.
Related Stories
Download this checklist for an at-a-glance view of important considerations when modernizing your health system’s infusion service line.
The most downloaded content by health system pharmacy leaders in August 2025.
With available labor resources dwindling and a shrinking pipeline, health systems must find creative solutions for better using the personnel and partnerships they have.
At this year's event, our experts heard from health systems who may be underutilizing available tools and resources in 340B program management.
Click through this interactive experience for a closer look at what you can expect at this year’s HealthTrust University Conference.
Our experts continue shaping industry conversations through regular conference and event engagements, like the HealthTrust University 340B Summit.
The most downloaded content by health system pharmacy leaders in July 2025.
A recent podcast includes first-hand insights on opportunities for collaboration in strengthening the supply chain to achieve more.
McKesson’s Head of Cell, Gene, and Advanced Therapies discusses opportunities and challenges with CGT in the health system.